Novartis has agreed to pay $245M to settle a lawsuit claiming the company attempted to delay the launch of generic copies of its Exforge blood-pressure medicine, Marthe Fourcade of Bloomberg reports. If the settlement is approved by a judge, it will resolve all outstanding claims on the matter for Novartis, Bloomberg added, citing an emailed statement made by the company. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVS:
- Sandoz Canada supports Ontario policy change on biosimilars
- Novartis call volume above normal and directionally bullish
- Harrow Health signs binding agreement to acquire rights to ophthalmic products
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Novartis reports Phase 3 APPLY-PNH trial met both primary endpoints